Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332
| Autor: | Mark R. Green, Elizabeth Johnson, James W. Box, James E. Herndon, Diana Lake, Thomas J. Lynch |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Neutropenia Vinorelbine Vinblastine Internal medicine Vinorelbine Tartrate Antineoplastic Combined Chemotherapy Protocols medicine Humans Carcinoma Small Cell Lung cancer Aged Aged 80 and over Performance status business.industry Middle Aged medicine.disease Survival Analysis Regimen Doxorubicin Toxicity Female Neoplasm Recurrence Local business Febrile neutropenia medicine.drug |
| Zdroj: | American journal of clinical oncology. 27(1) |
| ISSN: | 1537-453X |
| Popis: | Small-cell lung cancer that progresses after initial response may still be sensitive to systemic treatment. This study assessed doxorubicin plus vinorelbine tartrate (Navelbine Injection) in patients who had no prior exposure to these agents. Treatment consisted of vinorelbine at 25 mg/m2 on days 1 and 8 and doxorubicin at 50 mg/m2 on day 1 of each 21-day cycle. The trial was stopped early because of excessive toxicity. The partial response rate was 26.7%. Toxicities included grade IV neutropenia in 73%, and febrile neutropenia and/or sepsis in 60%. Three patients died from sepsis during cycle 1. Performance status 2 was significantly associated with febrile neutropenia (p = 0.044). Although this regimen had some activity, the toxicity precluded further evaluation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|